 |
 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
4 May 1999 | Volume 130 Issue 9 | Pages 736-739
Background: An increased risk for fetal loss caused by placental thrombosis is probable in carriers of the factor V Leiden mutation but has not been demonstrated consistently in previous studies.
Objective: To determine the overall risk for fetal loss and the separate risks for miscarriage and stillbirth in carriers of the factor V Leiden mutation.
Design: Retrospective cohort study.
Setting: Three university hospitals.
Participants: 228 carriers of the factor V Leiden mutation (77 propositi, 151 relatives) and 121 noncarrier relatives (controls). All participants had been pregnant at least once.
Measurements: Risks for fetal loss, miscarriage (defined as fetal loss within 20 weeks of gestation), and stillbirth (defined as fetal loss after >20 weeks of gestation) in women and in pregnancies were estimated and compared in carriers and noncarriers. Adjusted odds ratios were calculated by using multiple regression analysis. A random-effects model was used for comparisons of pregnancies.
Results: Fetal loss occurred in 31.6% of carriers and 22.3% of noncarriers, miscarriage occurred in 29.4% of carriers and 17.4% of noncarriers, and stillbirth occurred in 5.7% of carriers and 5.0% of noncarriers. Fetal loss recurred in 10.1% of carriers and 4.1% of noncarriers (odds ratio, 2.60 [95% CI, 0.96 to 7.03]). Adjusted odds ratios were 2.12 (CI, 1.35 to 3.33) for fetal loss, 2.08 (CI, 1.33 to 3.25) for miscarriage, and 1.60 (CI, 0.58 to 4.43) for stillbirth when pregnancies in carriers and noncarriers were compared. Homozygous carriers had a greater risk for fetal loss (odds ratio, 2.01 [CI, 0.94 to 4.32]) and stillbirth (odds ratio, 4.85 [CI, 0.82 to 25.58]) than heterozygous carriers.
Conclusions: Carriers of the factor V Leiden mutation have a greater risk for fetal loss (particularly miscarriage) than noncarriers. These data further suggest a greater risk for recurrence of fetal loss in carriers than in noncarriers and a greater risk for fetal loss and stillbirth in homozygous carriers than in heterozygous carriers.
Author and Article Information
Grant Support: By a grant from the Praeventiefonds (no. 28-2783). Dr. Büller is an established investigator of the Netherlands Heart Association.
Requests for Reprints: Johan R. Meinardi, MD, Division of Haemostasis, Thrombosis, and Rheology, University Hospital Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.
Current Author Addresses: Drs. Meinardi and van der Meer: Division of Haemostasis, Thrombosis, and Rheology, University Hospital Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.
Drs. Middeldorp, Koopman, and Büller: Center for Haemostasis, Thrombosis, Atherosclerosis, and Inflammation Research, F-4, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.
Mr. de Kam: Trial Coordination Center, University Hospital Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.
Drs. van Pampus and Hamulyák: Department of Haematology, University Hospital Maastricht, P. Debyelaan 25, 6229 HX Maastricht, the Netherlands.
Dr. Prins: Department of Clinical Epidemiology and Biostatistics, J-2, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands. BRIEF COMMUNICATION
Increased Risk for Fetal Loss in Carriers of the Factor V Leiden Mutation
This article has been cited by other articles:
|
|
 |
|
  C. J. Glueck, P. Wang, N. Goldenberg, and L. Sieve Pregnancy Loss, Polycystic Ovary Syndrome, Thrombophilia, Hypofibrinolysis, Enoxaparin, Metformin Clinical and Applied Thrombosis/Hemostasis, October 1, 2004; 10(4): 323 - 334. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Brenner Clinical management of thrombophilia-related placental vascular complications Blood, June 1, 2004; 103(11): 4003 - 4009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Bloomenthal, P. von Dadelszen, R. Liston, L. Magee, and P. Tsang The effect of factor V Leiden carriage on maternal and fetal health Can. Med. Assoc. J., July 1, 2002; 167(1): 48 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Deda, D. Icagasioglu, H. Qaksen, and N. Akar Combined Genetic Defects in a Child With Ischemic Stroke: Case Report J Child Neurol, July 1, 2002; 17(7): 533 - 534. [Abstract] [PDF]
|
|
|
|
 |
|
 L. A. Hefler, C. B. Tempfer, M. T. Bashford, G. Unfried, R. Zeillinger, C. Schneeberger, H. Koelbl, F. Nagele, and J. C. Huber Polymorphisms of the angiotensinogen gene, the endothelial nitric oxide synthase gene, and the interleukin-1{beta} gene promoter in women with idiopathic recurrent miscarriage Mol. Hum. Reprod., January 1, 2002; 8(1): 95 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Bauer The Thrombophilias: Well-Defined Risk Factors with Uncertain Therapeutic Implications Ann Intern Med, September 4, 2001; 135(5): 367 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Pabinger, H. Grafenhofer, A. Kaider, A. Ilic, S. Eichinger, P. Quehenberger, P. Husslein, C. Mannhalter, and K. Lechner Preeclampsia and Fetal Loss in Women With a History of Venous Thromboembolism Arterioscler. Thromb. Vasc. Biol., May 1, 2001; 21(5): 874 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. G. Macik, J. H. Rand, and B. A. Konkle Thrombophilia: What's a Practitioner to Do? Hematology, January 1, 2001; 2001(1): 322 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Martinelli, E. Taioli, I. Cetin, A. Marinoni, S. Gerosa, M. V. Villa, M. Bozzo, and P. M. Mannucci Mutations in Coagulation Factors in Women with Unexplained Late Fetal Loss N. Engl. J. Med., October 5, 2000; 343(14): 1015 - 1018. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Meinardi, P. M. Pelsma, H. Koning, J. van der Meer, and K. Hamulyak Double-Homozygosity for Factor V Leiden and the Prothrombin Gene G20210A Variant in a Young Patient With Idiopathic Venous Thrombosis Blood, September 1, 1999; 94(5): 1828 - 1829. [Full Text] [PDF]
|
|
Article
